Journal article icon

Journal article

Engineering antisense oligonucleotides for targeted mRNA degradation through lysosomal trafficking †

Abstract:
Antisense oligonucleotides (ASOs) can modulate gene expression at the mRNA level, providing the ability to tackle conventionally undruggable targets and usher in an era of personalized medicine. A key mode of action for ASOs relies upon RNase H-engagement in the nucleus, however, most mature mRNA is present in the cytoplasm. This disconnect limits the efficacy and biomedical applications of ASOs. In this paper, we have established a new mechanism of action for achieving potent and targeted mRNA knockdown by leveraging a lysosomal degradation pathway. To achieve this, we employ autophagosome-tethering compound (ATTEC) technology that utilises bifunctional small molecules for lysosomal trafficking. In this manner, to induce degradation of target mRNA located in the cytoplasm, we conjugated an ATTEC warhead, ispinesib, to RNase H-inactive ASOs. These fully 2′-O-methylated RNase H-inactive ASOs have higher chemical stability and tighter mRNA binding than conventional ‘gapmer’ sequences, but cannot be recognised by RNase H. Using our lysosomal trafficking antisense oligonucleotide (LyTON) technology, we show significant lysosome-dependent knockdown of multiple molecular targets in various cell lines, via transfection and gymnotic uptake. The LyTON modification is also able to boost the knockdown efficacy of RNase H-active ‘gapmer’ ASOs. Engineered to degrade mRNA independent of RNase H recognition, LyTONs will enable gene silencing using oligonucleotide chemistries with higher chemical stability, tighter mRNA binding affinity, and improved cell delivery profiles. This will enable us to target a wider range of disease-relevant mRNA, potentially leading to the development of new therapies.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Publisher copy:
10.1039/d5sc03751d

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Sub department:
Radcliffe Department of Medicine
Role:
Author
ORCID:
0000-0001-6046-4577
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Sub department:
Radcliffe Department of Medicine
Role:
Author
ORCID:
0000-0002-0413-4271
More by this author
Institution:
University of Oxford
Division:
MPLS
Department:
Chemistry
Sub department:
Chemistry
Role:
Author
ORCID:
0000-0002-4224-798X


More from this funder
Funder identifier:
https://ror.org/03wnrjx87
More from this funder
Funder identifier:
https://ror.org/03x94j517
More from this funder
Funder identifier:
https://ror.org/029chgv08


Publisher:
Royal Society of Chemistry
Journal:
Chemical Science More from this journal
Publication date:
2025-06-09
Acceptance date:
2025-06-09
DOI:
EISSN:
2041-6539
ISSN:
2041-6520


Language:
English
Source identifiers:
3039724
Deposit date:
2025-06-20
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP